Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

9 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

ECOG Second Primary Form NCT01169337

- 16-06-15 - 1 Formulier, 4 Itemgroepen, 19 Data-elementen, 1 Taal
Itemgroepen: Header, Patient demographics, Second primary cancer assessment, Comments
ECOG Second Primary Form NCT01169337 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8B34F8AB-6B35-638A-E040-BB89AD4311DF

Multiple Myeloma and Plasma Cell Neoplasm null Pre-Study - S0522 Prestudy Form - 2459879v1.0 - S0522 Prestudy Form

- 20-09-21 - 1 Formulier, 6 Itemgroepen, 41 Data-elementen, 1 Taal
Itemgroepen: Header, PATIENT AND DISEASE DESCRIPTION, Laboratory Values, DISEASE HISTORY AND DIAGNOSIS, PRIOR TREATMENT RELATED TO THIS CANCER, Comments
S0522 Prestudy Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0F232910-2A2F-5CD7-E044-0003BA3F9857

Eligibility NCT00689936 Multiple Myeloma - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 47 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00689936

Eligibility NCT00777998 Multiple Myeloma - Eligibility

- 16-04-14 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00408746

Eligibility NCT00722566 Multiple Myeloma - Eligibility

- 15-04-14 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00722566

Multiple Myeloma and Plasma Cell Neoplasm NCT00644228 Pre-Study - Southwest Oncology Group S0777 Prestudy Form - 2656421v1.0 - Southwest Oncology Group S0777 Prestudy Form

- 20-09-21 - 1 Formulier, 8 Itemgroepen, 58 Data-elementen, 1 Taal
Itemgroepen: Header, Eligibility Verification:, Patient and Disease Description, Laboratory Values, Laboratory Values, continued, Disease History and Diagnosis, Prior Treatment Related To This Cancer, Comments
Southwest Oncology Group S0777 Prestudy Form Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=33319F8E-13F8-4E7C-E044-0003BA3F9857

Staging after Consolidation LenaMain-Study - Staging after Consolidation

- 17-03-16 - 1 Formulier, 8 Itemgroepen, 75 Data-elementen, 1 Taal
Itemgroepen: Monthly control visit with response evaluation, Parameter of multiple myeloma, Vital signs, Laboratory:Protein electrophoresis, Laboratory:Hematology, Laboratory:serum chemistry, Laboratory:pregnancy test, Quality of life
A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Protocol-Code: RV-MM-PI-280 EudraCT-Number: 2007-003945-33 Author: Claus Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr. med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann, Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-Studie: Prof. Roland Fenk, Düsseldorf Coordinating center for clinical trial Medical faculty of University Hospital Heinrich-Heine-University Scientific Director: Herr Dr. J. Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0) 211-81-19701 Fax: +49 (0) 211-81-19702

Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma NCT00920556 - Screening - Medical and Surgical History; Disease Stage at Study Entry; Classification of Disease at Study Entry; Cancer related Surgical History; Previous Anti-Neoplastic Therapy

- 27-02-19 - 1 Formulier, 9 Itemgroepen, 26 Data-elementen, 1 Taal
Itemgroepen: Adminstrative, Does the subject have any clinically significant medical or surgical history?, Medical and Surgical History, Disease Stage at Study Entry, Classification of Disease at Study Entry, Did the subject have previous cancer related surgical history?, Cancer related Surgical History, Previous Anti-Neoplastic Therapy, Previous Anti-Neoplastic Therapy
Study ID: 113222 Clinical Study ID: 113222 Study Title: A Phase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00920556 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name:5.0g SRT501 Trade Name: Bortezomib Study Indication: Multiple Myeloma

Eligibility Multiple Myeloma NCT00083538

- 24-01-16 - 1 Formulier, 2 Itemgroepen, 14 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally; ODM derived from: https://clinicaltrials.gov/show/NCT00083538

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial